# Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

> **NCT03760822** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 112 (actual)

## Conditions studied

- Stomach Cancer
- Stomach Neoplasm
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03760822
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-16
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2024-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760822, "Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03760822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*